Aclarion vs Ispecimen
Ispecimen is the larger business, with $1.9m of revenue in fiscal 2025 against $75,730 for Aclarion (25.5 times as much). Aclarion grew faster (65.6% against -79.2%). Ispecimen kept more of each dollar of sales as profit: a net margin of -543.7% against -9551.9%. Aclarion carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | AclarionACON, 2025 | IspecimenISPC, 2025 |
|---|---|---|
| Revenue | $75,730 | $1.9m |
| Revenue growth | 65.6% | -79.2% |
| Net income | −$7.2m | −$10.5m |
| Operating margin | -9312.5% | -465.4% |
| Net margin | -9551.9% | -543.7% |
| Return on equity | -104.8% | — |
| Free cash flow | −$7.2m | −$4.2m |
| Cash | $12.0m | $6.9m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 11 | — |
| Market value | $4.4m | $1.3m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 26 (Weak) |
| Insider trades, 12 months | 11 buys, 0 sales | 0 buys, 0 sales |